Is Novo Nordisk helping Americans save taxpayer money or ripping them off? The company’s CEO is scheduled to testify Tuesday ...

Wegovy is a once-weekly injection approved by the U.S. Food and Drug Administration (FDA) to treat obesity in people 12 and ...

Congress is pushing companies like Ozempic and Wegovy, which make weight loss drugs that have changed the lives of millions ...

Sima Sistani, who took up the CEO post at WW International two-and-a-half years ago, is out, according to the company.

Semaglutide, the underlying drug marketed as Ozempic and Wegovy, works by mimicking a hormone that triggers the body to feel ...

U.S. senators questioned Novo Nordisk CEO Lars Fruergaard Jørgensen about the high costs of the company's GLP-1 drugs, which include popular weight-loss drugs Wegovy and Ozempic. It comes after North ...

Novo Nordisk CEO commits to exploring ways to make weight-loss drugs more affordable for U.S. patients after hearing from ...

Our editors also may be in touch with follow-up questions. Due to a Wegovy shortage coupled with Ozempic’s weight loss effects going viral on social media, people without type 2 diabetes have ...

WW International announced Friday that CEO Sima Sistani would leave her role effective immediately. Tara Comonte, a ...

Novo Nordisk has struck back in its growing rivalry with Eli Lilly in the obesity market, with data showing a higher-dose version of its oral version of weight loss drug Wegovy hit the mark in a ...

After 12 weeks, weight loss with the drug was 13% of body weight, compared to 1% with placebo, which the company said was around twice the level achieved with Wegovy (semaglutide) at that time point.

Commissions we earn from partner links on this page do not affect our opinions or evaluations. Our editorial content is based on thorough research and guidance from the Forbes Health Advisory Board.